Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 7/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711639 | 0.98 | HDAC3 (0.40) | HDAC3HDAC1TP53PLCG2PTK2B | |
| SCHEMBL6707825 | 0.92 | HDAC3 (0.42) | HDAC3HDAC1TP53PLCG2PTK2B | |
| SCHEMBL6708858 | 0.92 | HDAC3 (0.42) | HDAC3HDAC1TP53PLCG2PTK2B | |
| SCHEMBL6714199 | 0.91 | HDAC3 (0.41) | HDAC3HDAC1TP53PLCG2PTK2B | |
| SCHEMBL6710257 | 0.91 | HDAC3 (0.43) | HDAC3HDAC1TP53MAPTLMNA | |
| SCHEMBL6707884 | 0.91 | HDAC3 (0.40) | HDAC3HDAC1TP53PLCG2PTK2B | |
| SCHEMBL6710315 | 0.89 | POLB (0.39) | HDAC3HDAC1TP53PLCG2PTK2B | |
| SCHEMBL6709957 | 0.89 | HDAC3 (0.41) | HDAC3HDAC1TP53MAPTLMNA | |
| SCHEMBL6710214 | 0.88 | HDAC3 (0.40) | HDAC3HDAC1TP53MAPTLMNA | |
| SCHEMBL6714268 | 0.88 | LMNA (0.39) | HDAC3HDAC1TP53PLCG2PTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | HDAC3 2281/4885HDAC1 1910/4885ADORA3 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.